David Fabrizio has over 12 years of experience in the drug and biomarker discovery industry, and most recently in the application of next generation sequencing technologies to discover methods for cancer immunotherapy response. David’s career began at Adnexus Therapeutics in 2004, where he co-lead the PD1/PDL1 pre-clinical drug discovery program, leading to an acquisition by Bristol Myers Squibb in 2007. While there, his work was awarded several issued patents, including for those describing novel PD-L1, EGFR and IGFR targeting therapeutics, as well as a method for improved drug pharmacokinetics. Additionally, David also invented a novel drug selection technology, ASCENT, to rapidly identify protein based therapeutic binders using a reconstituted mRNA/protein fusion system. In 2013, David joined the startup, AbVitro, and focused on developing an immune cell next-generation sequencing/antigen target identification platform, which was subsequently acquired by Juno Therapeutics. David joined Foundation medicine in 2015, and currently leads the Cancer Immunotherapy group, which is focused on utilizing next-generation sequencing to build methods to identify responders to cancer immunotherapies.